Remimazolam Besylate Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as ACACIA. It is marketed under 1 brand name, including BYFAVO. Available in 1 different strength, such as EQ 20MG BASE/VIAL, and administered through 1 route including POWDER;INTRAVENOUS.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"66531","ingredient":"REMIMAZOLAM BESYLATE","trade_name":"BYFAVO","family_id":"14f3613537a14ac19645","publication_number":"US9914738B2","cleaned_patent_number":"9914738","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-07-10","publication_date":"2018-03-13","legal_status":"Granted"} US9914738B2 Formulation 13 Mar, 2018 Granted 10 Jul, 2027
{"application_id":"66500","ingredient":"REMIMAZOLAM BESYLATE","trade_name":"BYFAVO","family_id":"14f3613537a14ac19645","publication_number":"US10472365B2","cleaned_patent_number":"10472365","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-07-10","publication_date":"2019-11-12","legal_status":"Granted"} US10472365B2 12 Nov, 2019 Granted 10 Jul, 2027
{"application_id":"66532","ingredient":"REMIMAZOLAM BESYLATE","trade_name":"BYFAVO","family_id":"14f3613537a14ac19645","publication_number":"US10961250B2","cleaned_patent_number":"10961250","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-07-10","publication_date":"2021-03-30","legal_status":"Granted"} US10961250B2 Formulation 30 Mar, 2021 Granted 10 Jul, 2027
{"application_id":"66530","ingredient":"REMIMAZOLAM BESYLATE","trade_name":"BYFAVO","family_id":"14f3613537a14ac19645","publication_number":"US9777007B2","cleaned_patent_number":"9777007","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-07-10","publication_date":"2017-10-03","legal_status":"Granted"} US9777007B2 Formulation 03 Oct, 2017 Granted 10 Jul, 2027
{"application_id":"66555","ingredient":"REMIMAZOLAM BESYLATE","trade_name":"BYFAVO","family_id":"ef70d262765a462ea64c","publication_number":"US9737547B2","cleaned_patent_number":"9737547","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-07","publication_date":"2017-08-22","legal_status":"Granted"} US9737547B2 22 Aug, 2017 Granted 07 Nov, 2031
{"application_id":"66558","ingredient":"REMIMAZOLAM BESYLATE","trade_name":"BYFAVO","family_id":"ef70d262765a462ea64c","publication_number":"US10342800B2","cleaned_patent_number":"10342800","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-07","publication_date":"2019-07-09","legal_status":"Granted"} US10342800B2 09 Jul, 2019 Granted 07 Nov, 2031
{"application_id":"66556","ingredient":"REMIMAZOLAM BESYLATE","trade_name":"BYFAVO","family_id":"ef70d262765a462ea64c","publication_number":"US10052334B2","cleaned_patent_number":"10052334","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-07","publication_date":"2018-08-21","legal_status":"Granted"} US10052334B2 21 Aug, 2018 Granted 07 Nov, 2031
{"application_id":"66559","ingredient":"REMIMAZOLAM BESYLATE","trade_name":"BYFAVO","family_id":"ef70d262765a462ea64c","publication_number":"US10722522B2","cleaned_patent_number":"10722522","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-07","publication_date":"2020-07-28","legal_status":"Patented case"} US10722522B2 28 Jul, 2020 Patented case 07 Nov, 2031
{"application_id":"66557","ingredient":"REMIMAZOLAM BESYLATE","trade_name":"BYFAVO","family_id":"ef70d262765a462ea64c","publication_number":"US10195210B2","cleaned_patent_number":"10195210","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-07","publication_date":"2019-02-05","legal_status":"Patented case"} US10195210B2 05 Feb, 2019 Patented case 07 Nov, 2031
{"application_id":"66554","ingredient":"REMIMAZOLAM BESYLATE","trade_name":"BYFAVO","family_id":"ef70d262765a462ea64c","publication_number":"US9561236B2","cleaned_patent_number":"9561236","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-04-30","publication_date":"2017-02-07","legal_status":"Patented case"} US9561236B2 07 Feb, 2017 Patented case 30 Apr, 2033
{"application_id":"66536","ingredient":"REMIMAZOLAM BESYLATE","trade_name":"BYFAVO","family_id":"ef70d262765a462ea64c","publication_number":"US9827251B1","cleaned_patent_number":"9827251","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-01-13","publication_date":"2017-11-28","legal_status":"Granted"} US9827251B2 28 Nov, 2017 Granted 13 Jan, 2034

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Remimazolam Besylate

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.